Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Metrion Biosciences
Metrion Biosciences
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Metrion Biosciences enhances High Throughput Screening services
Access to Enamine's compound collection enables greater flexibility and efficiencies in screening and target identification
Finance
Metrion Biosciences closes £3.7m new equity financing
Funds to be used to expand Metrion’s Cambridge UK laboratories and to enhance scientific and commercial capabilities
Regulatory
Metrion launches Good Laboratory Practice hERG screening service
This means the company is therefore able to offer GLP compliant hERG ion channel screening services to the global life sciences community
Drug Delivery
Metrion Biosciences launches HTS capability
“The launch of our HTS capability adds another layer of depth to our ion channel drug discovery services and complements our automated and conventional electrophysiology services"
Research & Development
Metrion and Bioqube to collaborate on drug discovery project
The project aims to identify novel ion channel inhibitors for autoimmune diseases
Finance
Metrion appoints Vice President for US Commercial Operations
The appointment is planned to support the company's next phase of growth in the US
Finance
Metrion Biosciences expands into Cambridge headquarters
The 12,000 sqft facility more than doubles the company’s laboratory space
Subscribe now